A new refrigerated barge service to Dongguan and an extended Air-Land Fresh Lane to Macao further strengthen Hong Kong’s status as the region’s international cargo gateway

SHENZHEN, CHINA - Media OutReach Newswire - 3 July 2026 - Huawei today announced that its patent licensing royalty rate for Wi‑Fi 7 technologies would be set at US$0.5 per unit for Wi Fi 7 compliant devices. This announcement underscores Huawei's dedication to fostering a healthy innovation ecosystem through fair, transparent, and predictable licensing practices. As the latest generation of Wi-Fi technologies, Wi-Fi 7 delivers dramatically higher throughput, lower latency, and greater reliability. Serving as much more than just a connectivity upgrade, it lays the groundwork for the next wave of digital transformation and opens up new possibilities for interactions between people and intelligent systems. As a leading contributor to the IEEE 802.11 standards family, Huawei has played a pivotal role in shaping Wi‑Fi 7 (802.11be) technologies and holds one of the largest portfolios of declared essential patents for Wi‑Fi 7. The company has invested a decade of research and substantial resources into developing the core technologies that make Wi-Fi 7 truly next generation. Huawei has thus emerged as a leader in the global Wi-Fi licensing landscape, and its patent license agreements had covered over 1.2 billion consumer electronic devices worldwide by the end of 2024. With today's announcement, Huawei provides clear advance notice of its Wi‑Fi 7 royalty rate, which is US$0.5 per unit for consumer‑grade Wi‑Fi 7 devices. Implementers may obtain licenses either through bilateral agreements or via patent pools, on FRAND (Fair, Reasonable, and Non-Discriminatory) terms. In July 2022, Huawei joined the Sisvel Wi‑Fi 6 patent pool as a founding member, concurrently becoming both a licensor and a licensee of the pool. The patent pool is a valuable option for the industry which in large provides a "one-stop" licensing solution under a transparent and fair framework with lower transactions costs. Huawei also maintains a strong and proven Wi-Fi 6 patent portfolio, which has been widely recognized and licensed across the industry. This legacy of innovation across successive generations further demonstrates Huawei's long-term commitment to advancing wireless connectivity. Building on this success, Huawei has extended its participation to the Sisvel Wi‑Fi Multimode pool as a founding member, offering licensees a single, streamlined platform for accessing essential patents across both Wi‑Fi 6 and Wi‑Fi 7 generations. Alan Fan, Huawei's Chief Intellectual Property Officer, said: "Through these initiatives, Huawei continues to facilitate collaborative licensing models that balance the interests of innovators and implementers, further reinforcing its leadership in shaping a transparent and efficient global Wi-Fi licensing environment." For more information on Huawei's Wi‑Fi 7 licensing program, please visit [Huawei IP licensing webpage]. Hashtag: #Huawei The issuer is solely responsible for the content of this announcement.

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager (“BiTAC-TCE”) program through a collaboration with ATUM, which will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines supporting IND/CTA-enabling activities and future clinical development. The collaboration follows encouraging preclinical data presented at the 2026 American Association for […]

Greenland Energy (NASDAQ: GLND) is advancing a significant opportunity in Greenland’s Jameson Land Basin, one of the world’s largest remaining underexplored onshore hydrocarbon regions spanning more than 8,400 square kilometers. Under an agreement with 80 Mile, Greenland Energy will fully fund a two-well drilling program planned for the second half of 2026, earning a 70% interest […]

Transaction Valued at $122.5M Establishes 20,000-Liter US Biologics Drug Substance Manufacturing Platform, Covering Development through Commercial SupplyTAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics. With the close of the transaction, Bora Group's biologics CDMO franchise, Bora Biologics, now operates 20,000 liters of single-use bioreactor (SUB) drug substance manufacturing capacity across two active US sites: Rockville, Maryland and San Diego, California, and one development facility in Zhubei, Taiwan. "This acquisition establishes a US biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply," said Bobby Sheng, Chairman and CEO of Bora Group. "As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure. Bora Biologics is designed to meet that need, offering a fully integrated, end-to-end biologics platform spanning drug substance and drug product capabilities." With the addition of the Rockville facility, Bora Biologics supports more than 4 active commercial programs, with more than 120 completed GMP batches and supply into multiple global markets including the US, EU, Japan, Canada and the UK with fully integrated QC and analytical capabilities. Across its US network, Bora Biologics has completed five FDA inspections, including two at Rockville and one PMDA review in 2025, with clean results at both sites. The combined platform has supported more than 33 biologics and 15 biosimilars, establishing a manufacturing base for biotech and pharmaceutical companies with reduced offshore dependency and domestically anchored infrastructure. Bora Group intends to integrate its US drug substance (DS) capabilities with its existing sterile drug product (DP) capabilities over the next 12 to 18 months, offering a seamless, fully integrated development-through-commercial biologics solution. Hashtag: #BoraPharmaceuticalsThe issuer is solely responsible for the content of this announcement.About BoraFounded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life. By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries. For more, please visit: https://www.bora-corp.com https://www.boracdmo.com Disclaimer: This document and the accompanying information may contain forward-looking statements. All statements regarding the company's future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company's control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.

Beeline Holdings (NASDAQ: BLNE) announced the completion of its acquisition of artificial intelligence company MagicBlocks, whose technology powers the company’s proprietary AI agent, Bob, and supports automation across its mortgage origination and title operations. The company said full ownership of the technology is expected to accelerate AI-driven automation, reduce production costs and improve the speed and consistency of the borrower experience. […]